<DOC>
	<DOCNO>NCT00455975</DOCNO>
	<brief_summary>This trial examine effectiveness side effect 2 high dosing schedule bevacizumab patient advance clear cell renal carcinoma .</brief_summary>
	<brief_title>High-dose Bevacizumab Advanced Renal Carcinoma Patients</brief_title>
	<detailed_description>Bevacizumab consider targeted drug . Targeted drug act specific receptor cell . Bevacizumab block receptor help cancer cell develop blood supply cancer grow . These specific receptor find great number kidney cancer . In regard bevacizumab test 2 dos higher non-kidney cancer treatment bevacizumab . One group patient receive bevacizumab 15 mg per kg vein every 2 week . A total 75 patient treat dose . If dose well tolerated second group patient receive bevacizumab 15mg per kg vein weekly .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Histologically document metastatic unresectable locally recurrent clear cell renal carcinoma Previous kidney removal require except primary tumor small 5 cm extensive liver bone metastasis Patients may receive maximum 1 prior systemic treatment immunotherapy ( Interferon , IL2 ) , chemotherapy , combination chemo+immunotherapy metastatic disease . No prior bevacizumab Measurable disease Adequate liver kidney function Age 18 old Acute MI within past 6 month Uncontrolled high blood pressure history hypertensive crisis Clinically significant cardiovascular disease Active brain cancer Meningeal metastasis Pregnant lactating woman Prior treatment another cancer le 5 year ago No disease central nervous system ( eg . uncontrolled seizure , stroke TIAs No bleeding mouth , rectum cough blood history bleed clot disorder No history deep vein thrombosis le 12 month ago currently require full dose anticoagulation No major surgical procedure , open biopsy traumatic injury past 28 day No patient peg tubes feeding tube No patient non heal wound , ulcer long bone fracture No history abdominal fistula , gastrointestinal perforation intrabdominal abscess within 6 month No symptomatic peripheral vascular disease Please note : additional inclusion/exclusion criterion . The study center determine meet criterion . If qualify trial , study personnel explain reason . If qualify , study personnel explain trial detail answer question may . You decide wish participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Kidney Cancer</keyword>
	<keyword>Renal Cancer</keyword>
	<keyword>Clear Cell Carcinoma</keyword>
</DOC>